Who
Lynn Seely
President and CEO
Company insider
Files Form 4 as: President and CEO, Lyell Immunopharma; Director, AbCellera Biologics; Director, Blueprint Medicines; Principal Executive Officer, Myovant Sciences; Chief Medical Officer, Medivation.
In numbers
- Trades disclosed
- 235
- Buys
- 1
- Sells
- 48
- Bought
- $107K
- Sold
- $39.4M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 16 Mar 2007
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $149K9,589 at $15.54 | filing |
| 21 Aug 2026filed 25 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $149K9,589 at $15.54 | filing |
| 10 Aug 2026filed 11 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $5,593390 at $14.34 | filing |
| 10 Aug 2026filed 11 Aug 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $5,593390 at $14.34 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,207 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,207 at $0.00 | filing |
| 11 May 2026filed 15 Jun 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $7,337388 at $18.91 | filing |
| 11 May 2026filed 15 Jun 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $7,337388 at $18.91 | filing |
| 11 Feb 2026filed 12 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $174K7,455 at $23.39 | filing |
| 11 Feb 2026filed 12 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $174K7,455 at $23.39 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $10K438 at $23.12 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $10K438 at $23.12 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $6,637412 at $16.11 | filing |
| 27 Oct 2025filed 29 Oct 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 21 Aug 2025filed 22 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $76K7,257 at $10.54 | filing |
| 20 Aug 2025filed 22 Aug 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Lyell Immunopharma (NASDAQ:LYEL) versus Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical ComparisonLYEL · themarketsdaily.com · 20 Oct 2026Reviewing Neuphoria Therapeutics (NASDAQ:NEUP) & Lyell Immunopharma (NASDAQ:LYEL)LYEL · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Lynn Seely; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.